Devon shedlock poseida
Web"We are pleased to present preclinical data from our anti-c-kit CAR-T program demonstrating the broad capabilities of our platform technologies to potentially improve patient outcomes," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics. "P-ckit-ALLO1 is an allogeneic or 'off-the-shelf' adoptive cell … WebHeading up the immuno-oncology research effort for Poseida at JLABS is Devon Shedlock, Ph.D., current Director of Immuno-Oncology at Poseida and the former Associate Director of the T-Cell Engineering Core that is part of Carl June's group at the University of Pennsylvania. ... Poseida is a therapeutics-focused biotechnology company …
Devon shedlock poseida
Did you know?
WebIn addition, Dr. Devon Shedlock, Senior Vice President, Research & Development at Poseida, has invented a technology that we call the booster molecule, which uniquely allows Poseida to maintain the Tscm cells in our fully allogeneic products, while expanding the cells to create hundreds of doses from a single manufacturing run from a single ... WebAug 3, 2024 · "We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida's unique allogeneic approach to develop CAR-T product candidates," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. "Using our proprietary technologies and manufacturing process including our booster molecule, we …
WebAug 31, 2024 · Poseida's management team will host a conference call and webcast today, August 31, 2024 at 11:00am ET. The dial-in conference call numbers for domestic and international callers are (866) 939-3921 and (678) 302-3550, respectively. ... Presenter: Devon Shedlock, Ph.D., SVP Research & Development, Poseida Therapeutics. WebOct 14, 2024 · CGT Live October 14, 2024
WebOct 13, 2024 · SAN DIEGO, Oct. 13, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team. … WebDevon Shedlock; Poseida, San Diego, CA, USA; Abstract. Background MUC1 is a highly glycosylated protein that is expressed at the apical border of mucosal epithelium where it plays a protective role. MUC1 is comprised of an N-terminal subunit (MUC1N) tethered to a C-terminal subunit (MUC1C), forming a stable complex on the cell surface. A ...
WebWe are thrilled to partner with Roche using Poseida’s unique allogeneic approach to develop novel CAR-T product candidates. With our proprietary technologies… 10 …
WebJan 23, 2024 · Now, Gwinnett County District Attorney Danny Porter said he is seeking the death penalty against Devin Moon. Back in May 2024, Porter told 11Alive he would be … kinsey browningWebOct 21, 2024 · Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create … kinsey carson reeveslyndhurst school dukinfieldWebLinked companies : Poseida Therapeutics, Inc. Summary. Devon J. Shedlock is Chief Scientific Officer-Cell Therapies at Poseida Therapeutics, Inc. He received an … lyndhurst school oldhamWebOct 14, 2024 · Devon J. Shedlock, PhD, chief scientific officer, cell therapy, at Poseida Therapeutics, gave a presentation entitled “A Fully Allogeneic T scm-based TCR-T Platform for Cncology & Beyond” on Poseida’s … kinsey brown valporaiso universityWebOct 13, 2024 · Joining Poseida as its first employee in 2015, Dr. Shedlock was most recently Senior Vice President of Research & Development, serving as a key scientific … kinsey briceno louisianaWebAug 31, 2024 · Presenter: Devon Shedlock, ... Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as ... lyndhurst senior center